Anthropic updated its financials in an amended SEC filing, showing $33.24 billion revenue for the nine months ended September 30, a 1,200% increase from last year. Despite the revenue surge, the AI company reported a $104 billion net loss during the period, largely due to infrastructure costs and changes in convertible notes value. The company is preparing for a major IPO and has committed nearly $895 billion in spending on compute and infrastructure. This highlights both rapid growth and high capital intensity in the AI sector.
Anthropic's amended IPO prospectus reveals rapid revenue growth and large net losses. For readers following the Technology sector, here is Pluang's market snapshot as of Nov 02, 2026 21:41 WIB: out of 150 priced US stocks, 71 rose and 75 fell. Notable movers include STX at USD 621.87 (-3.52%), APLD at USD 17.20 (-3.48%), and BTDR at USD 6.49 (-3.28%).
Thailand's textile market is projected to grow from USD 4.97 billion in 2026 to USD 5.39 billion by 2032, at a CAGR of 1.31%. Growth is fueled by domestic fiber production, machinery upgrades, and rising demand for faster garment replenishment, espec...
A SEON survey of 2,026 U.S. adults reveals that while 68% use AI agents weekly for personal tasks, half are uncomfortable letting AI handle credit card purchases. Only 15% would share financial info with AI, and 43% lack confidence in spotting fraudu...
Callan JMB has received and will install a QuickStrip™ oral thin-film production line from Rapid Dose Therapeutics at its Texas facility, marking a key step in expanding its domestic pharmaceutical manufacturing. This new capability aims to produce f...
Known, a company developing accountability infrastructure for autonomous AI, announced that Edna Conway, former senior security executive at Microsoft and Cisco, has joined its Advisory Council. Conway brings extensive experience in cybersecurity and...
Radiopharm Theranostics announced progress in its oncology radiopharmaceutical pipeline, including preparing for a pivotal Phase 3 imaging trial of RAD101 for recurrent brain metastases after a successful FDA End-of-Phase 2 meeting. The company also ...
